InforMing the PAthway of COPD Treatment (IMPACT Study)-Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Results Based on an Analysis of the North American Region